米R-922减轻了LPS诱导的HK-2细胞亡和通过TGF-β/Smad的炎症
1Graduate School, Heilongjiang University of Chinese Medicine, Harbin, China.
Nucleosides, nucleotides & nucleic acids
|June 22, 2025
概括
微RNA-922 (miR-922) 通过调节TGF-β/Smad通路,保护细胞免受损伤. 兴奋剂miR-922可以缓解慢性病 (CKD) 中的亡和炎症.
科学领域:
- 分子生物学分子生物学
- 腎臟病學 (nephrology) 是一種醫學專業.
- 生物化学 生物化学
背景情况:
- 微RNA与慢性病 (CKD) 有关.
- 微RNA-922 (miR-922) 在CKD病原体中的特定作用仍然在很大程度上未被描述.
- 了解miR-922的功能对于CKD潜在的治疗策略至关重要.
研究的目的:
- 阐明miR-922在慢性病 (CKD) 背景下的机械作用.
- 研究miR-922如何影响损伤相关的细胞过程.
主要方法:
- 一个慢性病 (CKD) 细胞模型是使用人体临近管 HK-2 细胞与脂多糖 (LPS) 治疗建立的.
- 使用RT-qPCR和西部涂抹测量了miR-922,TGFβR1和p-Smad2/3的表达水平.
- 通过双露西法酶记者测定证实了miR-922和TGFβR1之间的直接相互作用.
- 细胞活力,细胞亡和炎症性细胞因子水平 (TNF-α,IL-1β) 分别使用CCK-8,Annexin V/PI染色和ELISA进行评估.
主要成果:
- 随着LPS治疗,HK-2细胞中的miR-922表达显著下降.
- miR-922直接准并降低TGFβR1的表达.
- 过度表达miR-922抑制了TGFβR1,从而抑制了Smad2/3的激活.
- 恢复miR-922水平或抑制Smad2/3减弱的LPS诱导的HK-2细胞的亡和炎症.
- 在这个CKD模型中,TGFβR1被确定为一种促亡和促炎因素.
结论:
- miR-922通过对TGF-β/Smad通路的负调节来缓解LPS诱导的亡和管细胞的炎症.
- 这种由miR-922介导的机制代表了慢性病 (CKD) 发展的潜在显著分子途径.
相关概念视频
NF-κB-dependent Signaling Pathway
7.9K
The transcription factor NF-κB was discovered in 1986 in the lab of Nobel laureate Professor David Baltimore, for its interaction with the immunoglobulin light chain enhancer in B-cells. After more than three decades of study, it is now evident that NF-κB regulates the expression of over 100 genes. Most of these genes play an essential role in the innate and adaptive immune responses as well as the inflammatory responses of animals.
NF-κB-dependent Signaling Mechanism
The...
NF-κB-dependent Signaling Mechanism
The...
7.9K
TGF - β Signaling Pathway
7.7K
The TGF-β signaling pathway regulates cell growth, differentiation, adhesion, motility, and development. TGF-β ligands that induce TGF-β signaling are synthesized in their latent form. Several proteases or cell surface receptors such as integrins act upon the latent form, releasing the active ligand. There are three types of mammalian TGF-βs: (TGF-β1, TGF-β2, and TGF-β3) that bind as homodimers or heterodimers to TGF-β receptors. The TGF-β receptors...
7.7K


